Development of a VHH-Based Erythropoietin Quantification Assay

Area of Science:

• Biotechnology
• Analytical Chemistry
• Bioprocess Engineering

Background:

• Traditional erythropoietin (EPO) quantification methods like ELISA and HPLC have limitations.
• Accurate EPO measurement is crucial for cell line selection and bioreactor cultivation in biopharmaceutical production.
• Existing techniques can be time-consuming, costly, or lack the required sensitivity for high-throughput screening.

Purpose of the Study:

• To develop and evaluate a novel, label-free assay for quantifying human recombinant erythropoietin (EPO).
• To assess the suitability of a camelid single-domain antibody fragment as a capturing agent in a biolayer interferometry assay.
• To enable rapid and robust EPO quantification in Chinese hamster ovary (CHO) cell supernatants for bioprocess monitoring.

Main Methods:

• Development of a label-free quantification assay utilizing biolayer interferometry.
• Employing a camelid single-domain antibody fragment, specific to human EPO, as the capture antibody.
• Testing the assay's performance with human recombinant EPO in Chinese hamster ovary cell culture supernatants.

Main Results:

• Specific detection of human recombinant EPO in CHO cell supernatants was achieved.
• The assay demonstrated sensitivity and a notable pH-dependent detection profile.
• The developed method proved to be rapid and robust, suitable for high-throughput applications.

Conclusions:

• A novel, label-free biolayer interferometry assay provides a sensitive and efficient method for EPO quantification.
• This assay overcomes drawbacks associated with traditional ELISA and HPLC methods.
• The new technique supports high-throughput analysis, facilitating improved cell line selection and bioprocess optimization.